Latest Biosimilar Stories
Payers Employ a Variety of Cost-Control Measures to Manage the Utilization of Premium-Priced RA Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
FDA has published a newlist of licensed biological products and interchangeable biosimilars, the “Purple Book”, which is being hyped as being the biological equivalent of the pharmaceutical
Launches discussion about the future of biosimilars in Italy ROME, Oct.
North America is the largest contributor to the global market while Asia is expected to grow at the highest rate.
Introduces Chairman Gewanter, shows support for BQ proposal GENEVA, Oct.
A Substantial Need Remains for Emerging SLE Biologics That Can Prevent Acute Flares and That Treat Severe Manifestations, According to Findings from Decision Resources Group BURLINGTON, Mass.,
- In medieval musical notation, a sign or neume denoting a shake or trill.